We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+14.13%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$24.4B
AUM Growth
+$627M
Cap. Flow
-$540M
Cap. Flow %
-2.21%
Top 10 Hldgs %
48.29%
Holding
168
New
24
Increased
37
Reduced
33
Closed
24

Sector Composition

Rank Sector Weight
1 Healthcare 33.14%
2 Technology 11.51%
3 Financials 9.33%
4 Communication Services 4.99%
5 Industrials 4.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ADI icon
26
Analog Devices
ADI
$190B
$319M 1.31%
1,299,500
+27,300
+2% +$6.56M
SCHW
27
Charles Schwab
SCHW
$187B
$310M 1.27%
3,251,657
-707,400
-18% -$67.1M
NYT icon
28
New York Times
NYT
$10.2B
$286M 1.17%
4,985,745
-623,801
-11% -$35.6M
LLY icon
29
PUT
Eli Lilly
LLY
$1.06T
$286M 1.17%
+375,000
New +$279M
GOOG icon
30
Alphabet (Google) Class C
GOOG
$4.32T
$273M 1.12%
1,120,940
-640,900
-36% -$135M
CBRE icon
31
CBRE Group
CBRE
$42.9B
$255M 1.04%
1,616,038
-497,100
-24% -$76.9M
MCK icon
32
McKesson
MCK
$101B
$253M 1.03%
327,100
+12,500
+4% +$8.8M
BEAM icon
33
Beam Therapeutics
BEAM
$2.84B
$244M 1%
10,063,111
+50,000
+0.5% +$995K
CRNX icon
34
Crinetics Pharmaceuticals
CRNX
$8.92B
$240M 0.98%
5,770,098
+1,124,000
+24% +$35.9M
ETHA
35
iShares Ethereum Trust ETF
ETHA
$5.55B
$235M 0.96%
+7,450,730
New +$221M
AGIO icon
36
Agios Pharmaceuticals
AGIO
$1.93B
$232M 0.95%
5,781,066
+13,600
+0.2% +$512K
V icon
37
Visa
V
$677B
$205M 0.84%
599,810
+291,000
+94% +$101M
LQDA icon
38
Liquidia Corp
LQDA
$8.02B
$195M 0.8%
8,565,638
+4,326,876
+102% +$93.9M
NSC icon
39
Norfolk Southern
NSC
$75.1B
$185M 0.76%
+615,000
New +$171M
LNTH icon
40
Lantheus
LNTH
$6.59B
$178M 0.73%
3,477,227
-3,245,000
-48% -$203M
IQV icon
41
IQVIA
IQV
$39.3B
$178M 0.73%
938,551
-2,912,800
-76% -$530M
WWD icon
42
Woodward
WWD
$21.4B
$157M 0.64%
621,973
-292,700
-32% -$72.7M
MA icon
43
Mastercard
MA
$493B
$122M 0.5%
213,771
+61,700
+41% +$35.4M
CNTA
44
DELISTED
Centessa Pharmaceuticals
CNTA
$105M 0.43%
4,331,318
-198,000
-4% -$3.52M
TEVA icon
45
Teva Pharmaceuticals
TEVA
$41.2B
$101M 0.41%
+4,997,000
New +$87.8M
TNGX icon
46
Tango Therapeutics
TNGX
$4.41B
$90.4M 0.37%
10,757,000
+1,600,000
+17% +$10.8M
BBNX
47
Beta Bionics
BBNX
$715M
$85.7M 0.35%
4,313,920
+110,000
+3% +$1.93M
THC icon
48
Tenet Healthcare
THC
$21.1B
$84.1M 0.34%
414,000
-115,000
-22% -$20.4M
GRAL
49
GRAIL Inc
GRAL
$3.1B
$79.8M 0.33%
1,349,000
+847,000
+169% +$32.4M
EHC icon
50
Encompass Health
EHC
$12.4B
$72.5M 0.3%
571,000
-137,000
-19% -$16.3M

Similar funds

Farallon Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Farallon Capital Management held 168 positions worth $24.4B, up 2.6% from $23.8B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Farallon Capital Management's Q3 2025 filing shows 24 new, 37 increased, 33 reduced and 24 closed positions. Its largest new stake was iShares Ethereum Trust ETF: 7,450,730 shares worth $235M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $3.53B.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 33% a quarter earlier, followed by Technology and Financials.

  • Farallon Capital Management's largest Q3 2025 buy was iShares Ethereum Trust ETF: 7,450,730 shares worth $235M.
  • Farallon Capital Management added most to Wabtec in Q3 2025, an estimated $177M increase.
  • Farallon Capital Management's biggest Q3 2025 reduction was IQVIA, cutting an estimated $530M.
  • Farallon Capital Management fully exited State Street SPDR S&P 500 ETF Trust in Q3 2025, selling an estimated $3.53B.
  • Farallon Capital Management's ten largest holdings make up 48% of its $24.4B portfolio in Q3 2025.
  • Farallon Capital Management opened 24 new positions and closed 24 in Q3 2025.
  • Farallon Capital Management's portfolio value rose 2.6% quarter-over-quarter to $24.4B.

Based on Farallon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.